Ad copy

I Performed 1,800 Prostatectomies. Then I Had One Myself. The Recovery Protocol I'd Been Prescribing Failed Me — Just Like It Failed Them. My name is Dr. Thomas Wright. I'm a urologist. Over a 22-year career, I performed approximately 1,800 radical prostatectomies. Then, at 63, I had one myself. Gleason 7. Robotic. Nerve-sparing. Bilateral. The same operation I'd been performing for two decades. I knew exactly what to expect. I'd walked thousands of men through this conversation. I'd written the recovery protocol. I knew the outcomes data cold. I was wrong about most of it. What I'm going to share is something I should have understood ten thousand patient-visits ago. I didn't. The reason almost no urologist understands it is the entire purpose of this letter. If you've had a prostatectomy. If you're 12 to 24 months out. If pills barely worked or stopped working. If you tried the pump and abandoned it. If you're now on Trimix and watching it cause damage. If your urologist has used the words "implant consultation"— Read this carefully. I'll start where I started. Six weeks post-op, I tried sildenafil. Nothing. Tadalafil daily—slight pressure. No rigidity. I wasn't surprised. I'd told patients this would happen. The pills require nerve signaling. The nerves were stunned. I was patient. At three months I started the vacuum erection device. I'd handed these out for years. I'd never used one. The device produced something tube-shaped. Dark. Cold. My wife, Anne, looked at it once and said quietly, "We don't have to do this." The pump went into a closet. Seven months in. Two hundred and eleven days without a single morning erection. I started Trimix. The first injection produced something in about eight minutes. Not natural. Forced. I sat on the edge of the bed afterward and cried. I had pushed a 30-gauge needle into my own penis to manufacture an erection I used to wake up with. Trimix worked for about four months. Then it stopped working as well. I increased the dose. A bend started forming—what we call Peyronie's-pattern fibrosis. About 25 degrees. Leftward. Painful at the base. The thing that was supposed to be my last good option was scarring me from the inside. There were nights—I'm going to say this once— When I sat in my study at midnight, fully aware of the irony, looking at the same ED outcomes data I'd been quoting to patients for two decades, and thought: My penis might as well be dead. My patients had said that to me, sometimes verbatim, in the consult room. I had nodded. I had recommended an implant referral. I had not actually understood what they were telling me until I was the one saying it. That's when I started suspecting something was wrong with the protocol I'd been prescribing for two decades. The Trimix failure didn't make sense to me. I had counseled hundreds of men through Trimix induction. I knew the dose-response curve. I knew the failure rates. What I had never understood—and what no textbook I owned addressed—was why Trimix worked beautifully for some men for years and quit on others within months. I had filed it under "individual variation." That's the doctor's phrase for "I don't know." But sitting on the side of my own bed, looking at a curved, aching, shorter penis than I'd had a year earlier, I couldn't file it under variation anymore. It was happening to me. So I drove to my office on a Saturday and pulled my own old patient charts. I had ordered post-op total testosterone and free testosterone panels on most of my prostatectomy patients. Standard practice. The numbers had been sitting in their charts for years. I had never looked at them as a system. What I saw made me sit down. I pulled forty-three charts that afternoon. I cross-referenced them on a yellow legal pad—pre-op total testosterone, six-month post-op total testosterone, ED status at twelve months, intervention used. By the time I'd worked through twenty of them, my hand had stopped writing the column headers and started just writing the numbers. The pattern was already obvious. Twenty-two years of evidence I had been generating and not reading. The men whose Trimix kept working—their post-op total testosterone had stayed within 50 points of their pre-op baseline. The men whose Trimix lost effect, whose erections shortened, who came back to me asking about implants— Almost all of them had dropped 100 to 200 points within the first six post-op months. I had ordered the labs. I had filed the reports. I had never connected the testosterone collapse to the failing erections. I went home that night and looked up my own pre-op testosterone. 487. My most recent post-op draw, fourteen months out: 261. Free testosterone, near the floor of the assay. I had documented my own collapse and not seen it. But that still didn't explain everything. Low testosterone alone shouldn't cause Peyronie's-pattern curvature. It shouldn't cause the kind of shrinkage I was seeing in patients whose hormones came back fine. There was something else going on. I didn't know what. So I went into the literature myself. Over the next two weeks, evenings and Saturdays, I worked through whatever I could pull on cavernous tissue physiology after pelvic surgery. The textbook chapters I had relied on for two decades were silent on the question. The recent journal literature was not. Here is what I worked out, in plain English. When the cavernous nerves are traumatized during prostatectomy—even with so-called nerve-sparing technique, even when the nerves are physically intact—they stop signaling for a period of months. The penis loses its ability to generate spontaneous nocturnal tumescence. Without those nightly erections, the smooth muscle inside the corpora cavernosa is not getting cyclical oxygenation. The tissue is, in clinical terms, hypoxic. Chronically. For months. Hypoxic smooth muscle does two things. It dies, by apoptosis. And as it dies, it is replaced by fibrotic scar tissue. That's where the curvature comes from. That's where the shrinkage comes from. That's where the rigidity loss comes from. The tissue that used to expand and trap blood is being progressively replaced by tissue that can't expand and can't trap. Then it got worse. There was a second collapse running in parallel. The same surgical trauma—the inflammation, the medications, the stress response—depresses Leydig cell function and crashes endogenous testosterone production. Smooth muscle requires testosterone to maintain structural integrity. Low testosterone accelerates the apoptosis that hypoxia is already driving. Two problems. Feeding each other. A collapse with two engines. I sat with what I had worked out for a week before I let myself understand what it implied. Sildenafil and tadalafil are PDE5 inhibitors. They amplify a nerve signal. If the nerve isn't sending the signal—and post-operatively, for many men, it isn't— There is nothing to amplify. The pills cannot work. They were never going to work for me at six weeks. The vacuum pump creates negative pressure to draw blood mechanically. It does not repair smooth muscle. It does not restore testosterone. It does nothing for the underlying tissue. Trimix bypasses the nerve and forces vasodilation pharmacologically. It produces an erection. But it forces blood into tissue that is already hypoxic, already dying, already fibrosing— And the repeated, prolonged, supraphysiologic pressure accelerates the fibrosis. Trimix doesn't treat the damage. In men whose tissue is already compromised, it speeds it up. Every rung of the standard recovery ladder I had been prescribing for 22 years addressed neither problem. Not the testosterone collapse. Not the oxygen-starvation fibrosis. Each rung either bypassed the system entirely or accelerated the underlying damage. That's when I realized: my body wasn't broken. The protocol I'd been writing for 22 years was incomplete. It had never addressed what was actually happening inside my patients' tissue. And it wasn't addressing what was happening inside mine. Once I had the mechanism, I knew what I was looking for. I needed something that could do two things at the same time— Support endogenous testosterone production. And support local nitric oxide synthesis in the cavernous endothelium. There is no pharmaceutical that does both. So I started searching the literature for any compound that did. I expected to come up empty. What I found, in a randomized clinical trial, was something I had spent my entire career dismissing. The compound is called shilajit. A mineral resin that exudes from rock fissures at high altitude in the Himalayas. Used in Ayurvedic medicine for roughly 3,000 years. Western urology, including mine, had treated it as folk medicine. The trial changed my mind. Shilajit, properly sourced and dosed, contains over 85 trace minerals plus a class of compounds called fulvic acids. Two findings stopped me. First: the trial measured endogenous testosterone production rising over 90 days in men on therapeutic doses. Not exogenous testosterone replacement. Endogenous. Their own production, restoring itself. That addressed the first problem. Second: fulvic acid supports nitric oxide synthesis in the endothelium of the cavernous arteries—the local signaling that tells vessels to dilate, independent of central nerve signaling. It also supports cellular oxygen utilization in smooth muscle. That addressed the second problem. Both engines of the collapse. In one compound. The hormonal foundation and the local vascular function. Restoring the substrate the standard protocol had been ignoring. But there was a problem. Even with the right mechanism in hand, most shilajit on the market is contaminated. Most of it is harvested at 3,000 to 8,000 feet—near agriculture and roads. The resin absorbs heavy metals there. It is then heat-processed for shelf stability, which destroys the fulvic acid. And dosed at 250 to 500 mg when the therapeutic studies use 4,000 mg. The Amazon gummies are, as far as I can tell, underdosed and bioavailability-compromised. Fulvic acid does not survive the heat processing required to make a shelf-stable gummy. I spent six weeks trying to find a brand that met clinical-grade criteria. My usual channels—compounding pharmacies, specialty distributors—didn't carry shilajit. The retail market was a graveyard of underdosed powders and contaminated tinctures. I was about to give up. Then, at the AUA annual meeting that May, I ran into a colleague I'd known since residency. Now running a sexual medicine practice in California. In line at the conference coffee bar I mentioned I'd been looking into shilajit for post-prostatectomy patients. He didn't laugh. He said: "I've been recommending one brand to my patients for three years. Let me tell you why." His criteria matched the criteria I had just worked out from the literature. Plus things I hadn't thought of. Harvest above 16,000 feet—above the contamination line, where mineral concentrations are highest. Cold-water purification over 60 days. No solvents. No heat. Heavy metals removed. Fulvic acid preserved. Therapeutic dose at 4,000 mg per day. Third-party batch testing for heavy metals, microbial load, and fulvic acid content in the US. Certificates published per batch. The brand was Nexora. He had been tracking outcomes informally in his own post-prostatectomy patients for two years. Men who'd come to him after the standard protocol had failed. His clinical impressions matched what I'd worked out from the literature. I went home from the conference and sat with it for a week before ordering anything. Twenty-two years of Western-trained skepticism do not turn off because a colleague at a coffee bar showed you a certificate of analysis. I have sat through the dinner-with-pharma-reps version of every supplement pitch in the modern era. I know what theatrical product looks like. What overcame the resistance, in the end, was the literature I had already read on my own and the clinical track record my colleague had been quietly assembling. The mechanism was credible. The product met the criteria. I ordered a 3 month supply. Two gummies. With breakfast. That was my entire intervention. Here is what I documented. I'll skip the parts that don't matter. Week three. I caught myself reading without rereading the same paragraph four times. The mental fog of the post-surgical year had become baseline—the thing I'd stopped noticing. It started to lift. And I noticed it lifting. Week five. A partial morning erection. The first one in fourteen months. I lay there for several minutes not believing what I was looking at. I didn't tell Anne. I wasn't ready for it to mean anything yet. Week seven. Full morning rigidity. Straight. No bend. No pain. The Peyronie's-pattern curvature had not resolved. But it had not worsened. And the pain at the base of the shaft was gone. Week ten. We tried. Anne and I. No injection. No pump. No pill. The first time in close to two years. It worked. It wasn't theatrical. It wasn't mechanically forced. It was the way it used to be, before any of this. Anne cried afterward. She cried because she had not believed this was possible anymore. Neither had I. I'm now eleven months in. Total testosterone holding at 461. Free testosterone normal. Morning erections are not every day. But they are routine. The curvature is roughly half what it was. We are intimate, on average, twice a week. Two gummies in the morning. That is my entire regimen. Here is the math of the window you are in. Smooth muscle that has been replaced by fibrotic scar cannot be restored. The tissue that has died is not coming back. But the tissue that is hypoxic and dying—that tissue can be saved. If oxygen and testosterone return before the apoptosis completes. The further you are from surgery, the more of that tissue is gone. Every month on Trimix, with the supraphysiologic pressure I described, more of it is lost. Some of those men still had viable cavernous tissue I am now reasonably certain could have been solved without a implant. I did not know that then. I do now. Most of the men I performed implants on came to me believing they had no other option. I believed it too, when I was telling them. I was wrong. And I have to live with that. If you are scheduled for an implant consultation, here is what I would say if you walked into my office today. You have a window. If your last surgery was less than three years ago, the window is probably still open. The protocol you have been on has been treating around the damage instead of underneath it. Restoring the foundation—testosterone production, local oxygenation, smooth muscle integrity—is the intervention you were never offered. It worked for me. I am writing this because I had to find what I'm telling you myself. In my own bloodwork. In my patient charts. At a conference bar, the men in white coats handing patients implant consents do not have this information. I did not. I do now. Nexora's high-altitude shilajit gummies are $89.99 a bottle. The company offers a 90-day money-back guarantee. Full refund. Including on opened bottles. They sell only through their website. They do not sell on Amazon, because the Amazon channel is dominated by counterfeit, low-altitude, heat-processed product that would destroy their batch testing. I started seeing changes in week three. If the compound is going to work for you, you will know within the 90-day window the guarantee covers. I cannot tell you what your urologist has not told you. I can only tell you what I missed for 22 years and in my own bloodwork. The window is open until it closes. The implant ends the question permanently. I am not asking you to trust me. I am asking you to read the labs you already have and consider whether what you have been told is the full picture. If you want to try what I tried, the link is below. The risk is the cost of the bottle minus the guarantee. The risk of waiting is the tissue you cannot get back. I would have started this twenty months earlier if anyone had told me. No one did. I'm telling you.